Last reviewed 2026-04-19 · How we verify

rFIV vaccine

DynPort Vaccine Company LLC, A GDIT Company · Phase 2 active Biologic

rFIV vaccine is a Biologic drug developed by DynPort Vaccine Company LLC, A GDIT Company. It is currently in Phase 2 development. Also known as: Recombinant Plague Vaccine rF1V.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	rFIV vaccine
Also known as	Recombinant Plague Vaccine rF1V
Sponsor	DynPort Vaccine Company LLC, A GDIT Company
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

rFIV vaccine CI brief — competitive landscape report
rFIV vaccine updates RSS · CI watch RSS
DynPort Vaccine Company LLC, A GDIT Company portfolio CI

Frequently asked questions about rFIV vaccine

What is rFIV vaccine?

rFIV vaccine is a Biologic drug developed by DynPort Vaccine Company LLC, A GDIT Company.

Who makes rFIV vaccine?

rFIV vaccine is developed by DynPort Vaccine Company LLC, A GDIT Company (see full DynPort Vaccine Company LLC, A GDIT Company pipeline at /company/dynport-vaccine-company-llc-a-gdit-company).

Is rFIV vaccine also known as anything else?

rFIV vaccine is also known as Recombinant Plague Vaccine rF1V.

What development phase is rFIV vaccine in?

rFIV vaccine is in Phase 2.

Manufacturer: DynPort Vaccine Company LLC, A GDIT Company — full pipeline
Also known as: Recombinant Plague Vaccine rF1V

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing